Pathogenesis of Myeloma Bone Disease

被引:107
作者
Roodman, G. David [1 ]
机构
[1] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA
关键词
MYELOMA; BONE DISEASE; METASTASIS; TUMOR-NECROSIS-FACTOR; KAPPA-B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; INTERACTING PROTEIN P62; MULTIPLE-MYELOMA; RECEPTOR ACTIVATOR; OSTEOBLAST DIFFERENTIATION; IN-VIVO; MARROW MICROENVIRONMENT; CELL-GROWTH;
D O I
10.1002/jcb.22403
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple myeloma (mm) is the most common cancer to involve bone with Up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs front hone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor exceeds 50% in it local area, osteoblast activity is either severely depressed of absent. The basis For this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and Will he discussed in this chapter. J. Cell. Biochem. 109: 283-29 1, 2010. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:283 / 291
页数:9
相关论文
共 86 条
  • [1] Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
    Abe, M
    Hiura, K
    Wilde, J
    Shioyasono, A
    Moriyama, K
    Hashimoto, T
    Kido, S
    Oshima, T
    Shibata, H
    Ozaki, S
    Inoue, D
    Matsumoto, T
    [J]. BLOOD, 2004, 104 (08) : 2484 - 2491
  • [2] Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma
    Alsayed, Yazan
    Ngo, Hai
    Runnels, Judith
    Leleu, Xavier
    Singha, Ujjal K.
    Pitsillides, Costas M.
    Spencer, Joel A.
    Kimlinger, Teresa
    Ghobrial, Joanna M.
    Jia, Xiaoying
    Lu, Ganwei
    Timm, Michael
    Kumar, Ashok
    Cote, Daniel
    Veilleux, Israel
    Hedin, Karen E.
    Roodman, G. David
    WitZig, Thomas E.
    Kung, Andrew L.
    Hideshima, Teru
    Anderson, Kenneth C.
    Lin, Charles P.
    Ghobrial, Irene M.
    [J]. BLOOD, 2007, 109 (07) : 2708 - 2717
  • [3] Development of an in vivo model of human multiple myeloma bone disease
    Alsina, M
    Boyce, B
    Devlin, RD
    Anderson, JL
    Craig, F
    Mundy, GR
    Roodman, GD
    [J]. BLOOD, 1996, 87 (04) : 1495 - 1501
  • [4] Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
    Anderson, G
    Gries, M
    Kurihara, N
    Honjo, T
    Anderson, J
    Donnenberg, V
    Donnenberg, A
    Ghobrial, I
    Mapara, MY
    Stirling, D
    Roodman, D
    Lentzsch, S
    [J]. BLOOD, 2006, 107 (08) : 3098 - 3105
  • [5] New insights in myeloma-induced osteolysis
    Barillé-Nion, S
    Bataille, R
    [J]. LEUKEMIA & LYMPHOMA, 2003, 44 (09) : 1463 - 1467
  • [6] Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
    Berenson, JR
    Lichtenstein, A
    Porter, L
    Dimopoulos, MA
    Bordoni, R
    George, S
    Lipton, A
    Keller, A
    Ballester, O
    Kovacs, M
    Blacklock, H
    Bell, R
    Simeone, JF
    Reitsma, DJ
    Heffernan, M
    Seaman, J
    Knight, RD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 593 - 602
  • [7] A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
    Body, JJ
    Facon, T
    Coleman, RE
    Lipton, A
    Geurs, F
    Fan, M
    Holloway, D
    Peterson, MC
    Bekker, P
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1221 - 1228
  • [8] Osteoclast differentiation and activation
    Boyle, WJ
    Simonet, WS
    Lacey, DL
    [J]. NATURE, 2003, 423 (6937) : 337 - 342
  • [9] Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    Breitkreutz, I.
    Raab, M. S.
    Vallet, S.
    Hideshima, T.
    Raje, N.
    Mitsiades, C.
    Chauhan, D.
    Okawa, Y.
    Munshi, N. C.
    Richardson, P. G.
    Anderson, K. C.
    [J]. LEUKEMIA, 2008, 22 (10) : 1925 - 1932
  • [10] osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
    Bucay, N
    Sarosi, I
    Dunstan, CR
    Morony, S
    Tarpley, J
    Capparelli, C
    Scully, S
    Tan, HL
    Xu, WL
    Lacey, DL
    Boyle, WJ
    Simonet, WS
    [J]. GENES & DEVELOPMENT, 1998, 12 (09) : 1260 - 1268